Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Beate Schultheis"'
Autor:
Clemens B. Tempfer, Iris Tischoff, Askin Dogan, Ziad Hilal, Beate Schultheis, Peter Kern, Günther A. Rezniczek
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-16 (2018)
Abstract Background Neuroendocrine carcinoma of the cervix (NECC) is a rare variant of cervical cancer. The prognosis of women with NECC is poor and there is no standardized therapy for this type of malignancy based on controlled trials. Methods We p
Externí odkaz:
https://doaj.org/article/71d269fb93c14577918a5aaa5e6683ed
Autor:
Askin Dogan, Peter Kern, Beate Schultheis, Günther Häusler, Günther A. Rezniczek, Clemens B. Tempfer
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Radiogenic angiosarcoma of the breast (RASB) is a rare late sequela of local irradiation of the breast or chest wall after breast cancer. The prognosis of women with RASB is poor and there is no standardized therapy for this type
Externí odkaz:
https://doaj.org/article/1c7d3cc97e9549cd9aa7cfa78deff1d2
Autor:
Heiko Konig, Nicolai Härtel, Beate Schultheis, Michael Schatz, Christian Lorentz, Junia V. Melo, Rüdiger Hehlmann, Andreas Hochhaus, Paul La Rosée
Publikováno v:
Haematologica, Vol 92, Iss 6 (2007)
The development of resistance to imatinib mesylate may partly depend on high Bcr-Abl-expression levels. Arsenic trioxide (ATO) has Bcr-Abl suppressing activity in vitro. Here we investigated means to improve ATO activity in CML by modulating cellular
Externí odkaz:
https://doaj.org/article/cf48954c916c4710ab372bfecdc0b307
Autor:
Hartmut Döhner, Elisabeth Dietl, Daniela Weber, Anika Schrade, Julia Krzykalla, Michael Heuser, Verena I. Gaidzik, Anthony J. Wagner, Jürgen Krauter, Maral Saadati, Silke Kapp-Schwoerer, Holger Hebart, Juliane S. Walz, Verena Mayr-Benedikter, Felicitas Thol, Konstanze Döhner, Stefan Faderl, Peter Paschka, Nadezda Basara, Beate Schultheis, Michaela Feuring-Buske, Axel Benner, Arnold Ganser
Publikováno v:
Blood. 136:46-47
Background: CPX-351, a liposomal formulation of daunorubicin and cytarabine in the fixed molar ratio (1:5), is approved for the treatment of adult patients (pts) with newly diagnosed acute myeloid leukemia (AML) with myelodysplasia-related changes an
Publikováno v:
Oncology Letters
The present review aimed to assess the safety and efficacy of thalidomide and lenalidomide, two immunomodulatory drugs with anti-angiogenic properties, in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. A systematic revie
Autor:
Dirk Strumberg, Maurice Perol, Glen J. Weiss, Beate Schultheis, Fabrice Barlesi, Jean-Charles Soria, Hendrik Nogai, Gérard Zalcman, Rastislav Bahleda, Isabelle Ray-Coquard, Matthias Ocker, Martin Kornacker, Prabhu Rajagopalan, Juneko E. Grilley-Olson, Laurent Greillier, David Henderson, Grace K. Dy, Ramaswamy Govindan, Annette O. Walter
Publikováno v:
British Journal of Cancer
Background: To evaluate safety, pharmacokinetics, and maximum tolerated dose of roniciclib in patients with advanced malignancies, with dose expansion to evaluate clinical benefit at the recommended phase II dose (RP2D). Methods: Two phase I dose-esc
Autor:
Cem Cetin, Günther Häusler, Askin Dogan, Beate Schultheis, Günther A. Rezniczek, Clemens B. Tempfer, Ziad Hilal
Publikováno v:
Anticancer Research. 37:969-978
Background: Young women with endometrial cancer (EC) have an increased risk of synchronous ovarian cancer. The prognosis of women with synchronous endometrial and ovarian cancer (SEOC) is good. A high proportion of affected women have hereditary non-
Autor:
Günther A. Rezniczek, Askin Dogan, Violetta Rapi, Franziska Hartmann, Clemens B. Tempfer, Beate Schultheis
Publikováno v:
Anticancer Research. 37
Background Primary melanoma of the vagina (PMV) is a rare entity. The prognosis of women with PMV is poor and there is no standardized therapy for this type of malignancy. We present the case of a 72-year-old woman with PMV (cT2, pN0, M0). Case repor
Autor:
Beate Schultheis, Dirk Strumberg, David Diaz-Carballo, Sebastian Gustmann, Ulrike Dembinski, Constanze Aldinger, Philip Dammann, Jacqueline Klein, Holger Jastrow, Marcos J. Araúzo-Bravo, Walter Bardenheuer, Sascha Malak, Ali Haydar Acikelli
Publikováno v:
DNA and Cell Biology. 33:749-774
Until recently, acquired resistance to cytostatics had mostly been attributed to biochemical mechanisms such as decreased intake and/or increased efflux of therapeutics, enhanced DNA repair, and altered activity or deregulation of target proteins. Al
Autor:
Askin Dogan, Peter Kern, Beate Schultheis, Günther Häusler, Günther A. Rezniczek, Clemens B. Tempfer
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Background Radiogenic angiosarcoma of the breast (RASB) is a rare late sequela of local irradiation of the breast or chest wall after breast cancer. The prognosis of women with RASB is poor and there is no standardized therapy for this type of malign